title: Corneal crosslinking for progressive keratoconus in four children.
abstract: The authors describe four children with progressive keratoconus treated by corneal crosslinking (CXL). The current CXL guidelines recommend treatment of patients 18 years and older. Nevertheless, keratoconus can rapidly progress in young teenagers. CXL could be a safe procedure to prevent a keratoplasty at a young age.
authors.affiliation: Department of Ophthalmology, HP E03.136, University Medical Center Utrecht, Heidelberglaan 100, 3508 GX Utrecht, The Netherlands. N.Soeters@umcutrecht.nl
authors.forename: Nienke
authors.initials: N
authors.lastname: Soeters
authors.forename: Allegonda
authors.initials: A
authors.lastname: Van der Lelij
authors.forename: Rikkert
authors.initials: R
authors.lastname: van der Valk
authors.forename: Nayyirih G
authors.initials: NG
authors.lastname: Tahzib
mesh_terms: D000293:Adolescent; D002648:Child; D003094:Collagen / Q000378:metabolism*; D063171:Corneal Pachymetry; D003319:Corneal Stroma / Q000378:metabolism*; D019781:Corneal Topography; D003432:Cross-Linking Reagents / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007640:Keratoconus / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D017319:Photosensitizing Agents / Q000627:therapeutic use; D012256:Riboflavin / Q000627:therapeutic use; D014466:Ultraviolet Rays; D014792:Visual Acuity / Q000502:physiology
chemical_list: D003432:Cross-Linking Reagents; D017319:Photosensitizing Agents; D003094:Collagen; D012256:Riboflavin